hepatology

Page 4 of 8« First...23456...Last »

CTI BioPharma acquires worldwide privileges to tosedostat CTI BioPharma Corp.

Over the next year, CTI and its advisors intend to create a registration route for tosedostat in the US and Europe. In the event of positive clinical data and productive regulatory discussions, we would intend to take up a pivotal system commencing in 2016.’ Related StoriesOvarian cancer sufferers with a history of oral contraceptive make use of have better outcomesCrucial change in single DNA foundation predisposes children to intense type of cancerCornell biomedical engineers develop 'super organic killer cells' to destroy tumor cells in lymph nodesUnder the conditions of an asset purchase contract with Chroma, CTI acquired all of Chroma's right, name and curiosity in tosedostat and certain related assets in exchange for issuing to Chroma $21.3 million in shares of CTI's preferred share convertible into 9 million shares of CTI common share, 12 % of which has been placed in escrow pending expiry of Chroma's indemnification obligations. Continue reading

Those with vulnerable.

California’s SB 277 is a kind of medical genocide targeting genetically vulnerable children As some senators in California continue steadily to press onward in struggling to eliminate the proper of parents to opt their kids away of ‘mandatory’ vaccinations, those with vulnerable, or what some have got deemed ‘faulty,’ genetics are sounding the alarm about how exactly the potential passing of Senate Bill 277 will put them at a massively increased risk of suffering long lasting health damage tadalafil dosage . Just like certain foods and herbal products exert varying effects on people based on their individual genetic makeups, vaccines can cause serious damage in people with genetic ‘defects’ that impair the body’s ability to neutralize and get rid of poisons. Continue reading

Cadwaladers HEALTHCARE Fraud Strike Pressure to focus on health care.

With this initiative, we are bringing together seasoned litigators in the Company's decades-long health care practice with several past U.S. Lawyers and federal prosecutors who have deep experience in healthcare in order to better still serve our health and wellness care customers with a cohesive team of lawyers. Members of the Strike Force will continue to work in close collaboration with one another, and with our clients, in understanding each client's requirements and goals and in formulating effective and efficient strategies to achieve the very best outcome.’.. Cadwalader’s HEALTHCARE Fraud Strike Pressure to focus on health care, white collar and litigation practices Cadwalader, Wickersham & Taft LLP, a respected counselor to global financial institutions and corporations, launched a Health Care Fraud Strike Drive integrating the Firm's strong health care, white training collar and litigation practices. Continue reading

MCG nephrologist focusing on acute renal failing and a principal investigator on the analysis.

Even the contrast moderate needed to research kidney function could be toxic. Szerlip says. The multi-site research is normally funded by Boston-centered Nephros Therapeutics Inc.. Bioartificial kidney containing vast amounts of donor kidney cells in study in the Medical University of Georgia Whether a bioartificial kidney containing vast amounts of donor kidney cells can help intensive care individuals with kidney failure survive is under research at the Medical College of Georgia. MCG INFIRMARY has joined a report occurring in intensive care products across the country to judge the efficacy of the renal support gadget, says Dr. Continue reading

Axonics Modulation Systems completes $32.

‘We really possess the potential to consider that technology basis and quickly commercialize a next-era implantable neuromodulation system to take care of chronic pain via spinal-cord stimulation and peripheral nerve applications.’.. Axonics Modulation Systems completes $32.6 million Series A preferred stock financing Axonics Modulation Technology, Inc., a programmer of novel implantable neuromodulation technology, announced today that it offers finished a $32.6 million Series A preferred share financing. Continue reading

Page 4 of 8« First...23456...Last »